Victoria Socha

DocwireNews

According to Rajkumar Chinnadurai, MBBS, MD, and colleagues, guideline-directed therapy with renin-angiotensin-aldosterone system inhibitors is rarely achieved in clinical settings, due in part to the risk of hyperkalemia. The AMETHYST-DN trial was designed to assess the effect of patiromer, a potassium binder, on continuation of RAAAS inhibitor therapy in a population of patients with chronic kidney disease, type 2 diabetes mellitus, and hyperkalemia. Study participants were propensity-score matched to a real-word cohort not receiving patiromer.A total of 304 adults with CKD, type 2 diabetes, and hyperkalemia who were being treated with&nbsp; RAASA inhibitors were enrolled in the phase 2, open-label AMETHYST-DN trial and randomized to receive patiromer at doses of 8.4 to 33.6 g/day for 12 months.Propensity-score matching adjusted for systolic blood pressure, heart failure status, and estimated glomerular filtration rate (eGFR) matched the 304 participants with 321 participants in the prospective Salford Kidney Study with CKD, type 2 diabetes, hyperkalemia, and treatment with RAAS inhibitors. Mann-Whitney U or chi-squared tests were used to assess changes in RAAS inhibitor utilization, serum potassium level, blood pressure, proteinuria, and eGFR during 12 months of follow-up.After matching, the cohort included 135 patients who were matched in a 1:1 ratio to 135 patients who were similar in age, sex, systolic blood pressure, serum potassium level, eGFR, and heart failure status. There were differences between the two groups in diastolic blood pressure (P&lt;.01).At the 12-month follow-up, 100% of patients in the patiromer group remained on RAAS inhibitor therapy, compared with 38.5% of the Salford Kidney Study group who discontinued RAAS inhibitor therapay (P&lt;.001). Forty-two percent of the RAAS inhibitor discontinuations were associated with hyperkalemia.Patients in the patiromer group experienced greater reductions in serum potassium level and blood pressure, but no reductions in proteinuria or eGFR, compared with those in the Salford Kidney Study group (P&lt;.05)In conclusion, the authors said, &ldquo;These results demonstrate the benefit of patiromer for serum potassium management to enable RAAS inhibitor use, while revealing beneficial effects on blood pressure.&rdquo;Source: <a href="https://karger.com/ajn/article/doi/10.1159/000533753/863157/Maintaining-renin-angiotensin-aldosterone-system?searchresult=1" target="_blank" rel="noopener">American Journal of Nephrology</a>

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Latest News

Propensity Matching AMETHYST-DN and Real-World Population

Hyperkalemia

Guideline-directed therapy with renin-angiotensin-aldosterone system inhibitors is rarely achieved in clinical settings, due in part to the risk of hyperkalemia. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe